Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back a total of 200,000 ordinary fully paid securities on the previous day, adding to a cumulative total of 5,842,629 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services. It offers a range of diagnostic testing services to healthcare professionals and patients across Australia.
Average Trading Volume: 970,672
Technical Sentiment Signal: Sell
Current Market Cap: A$575.4M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.